BioVector? Super PiggyBac 轉(zhuǎn)座酶系統(tǒng)說(shuō)明書(shū)

BioVector? Super PiggyBac Transposase System Manual

第一部分 中文說(shuō)明

一 產(chǎn)品基本信息與系統(tǒng)背景

• 產(chǎn)品名稱(chēng)：BioVector? Super PiggyBac Transposase (含表達(dá)質(zhì)粒與純化重組蛋白系統(tǒng))

• 系統(tǒng)類(lèi)型：非病毒介導(dǎo)的哺乳動(dòng)物基因組高效整合轉(zhuǎn)座酶系統(tǒng)（Non-viral Transposon System）。

• 起源與工程化改良：

  • 天然起源：PiggyBac (PB) 轉(zhuǎn)座子系統(tǒng)最初自粉紋夜蛾（Trichoplusia ni）細(xì)胞中分離獲得。它屬于 DNA 轉(zhuǎn)座子（Class II Transposon），通過(guò)經(jīng)典的“剪切與粘貼（Cut-and-Paste）”機(jī)制發(fā)生轉(zhuǎn)座。

  • Super 改良：Super PiggyBac (sPBase) 是通過(guò)對(duì)天然 PiggyBac 轉(zhuǎn)座酶進(jìn)行大規(guī)模飽和氨基酸位點(diǎn)突變與理性設(shè)計(jì)而獲得的超強(qiáng)進(jìn)化版本。與天然型 PB 轉(zhuǎn)座酶相比，sPBase 的基因組整合效率提升了數(shù)倍至數(shù)十倍，即使面對(duì)超大分子量（超過(guò) 10 kb 到 100 kb）的基因外源片段，依然能保持強(qiáng)勁的染色體整合能力。

• 生物安全級(jí)別：1級(jí)（BSL-1）。作為完全非病毒源性的核酸底物，不產(chǎn)生任何具有復(fù)制能力的病毒顆粒，因而無(wú)需復(fù)雜的 BSL-2 等級(jí)防護(hù)，是現(xiàn)代基因工程中極安全的基因遞送工具。

二 轉(zhuǎn)座分子機(jī)制與靶向特征

Super PiggyBac 轉(zhuǎn)座酶專(zhuān)門(mén)識(shí)別并作用于轉(zhuǎn)座子載體兩端的反向末端重復(fù)序列（Inverted Terminal Repeats, ITRs）。其核心分子運(yùn)作圖譜如下：

[轉(zhuǎn)座子載體] ---> 5'-ITR ====== 目的基因 (GOI) ====== ITR-3'                           │ (被 sPBase 剪切)                           ▼[宿主基因組] ---> 5'-nnnnnn TTAA mmmmmm-3' （特異性插入 TTAA 位點(diǎn)）

1. 精準(zhǔn)剪切與粘貼（Cut-and-Paste Mechanism）：sPBase 蛋白特異性結(jié)合轉(zhuǎn)座子供體質(zhì)粒兩側(cè)的 5' ITR 和 3' ITR，形成立體的轉(zhuǎn)座復(fù)合物，隨后將整段目的基因盒（Expression Cassette）從質(zhì)粒骨架上無(wú)損完整剪切下來(lái)。

2. TTAA 位點(diǎn)特異性（TTAA-Specificity）：釋放出的轉(zhuǎn)座子片段被 sPBase 運(yùn)送至宿主細(xì)胞核內(nèi)，專(zhuān)門(mén)識(shí)別并整合到宿主染色體上帶有 5'-TTAA-3' 堿基序列的位點(diǎn)中。整合后，轉(zhuǎn)座子兩端將各形成一個(gè)重復(fù)的 TTAA 序列。

3. 無(wú)痕切除活性（Seamless Excision）：這是 PiggyBac 系統(tǒng)獨(dú)一無(wú)二的絕對(duì)優(yōu)勢(shì)。在后續(xù)需要時(shí)（如干細(xì)胞重編程中清除因子），重新引入轉(zhuǎn)座酶可以激活“反向轉(zhuǎn)座”，將整合在基因組中的片段從小鼠/人類(lèi)染色體中原樣切除并完全修復(fù)受體位點(diǎn)，不在基因組中留下任何外源突變、堿基缺失或疤痕（No scar/mutation left behind）。

三 實(shí)驗(yàn)操作、細(xì)胞轉(zhuǎn)染與穩(wěn)株篩選標(biāo)準(zhǔn)步驟

1. 轉(zhuǎn)染體系配置比例（Co-transfection Setup）：

   • 該系統(tǒng)屬于典型的雙質(zhì)粒系統(tǒng)（Helper-Donor System）：

     • Donor 質(zhì)粒（轉(zhuǎn)座子載體）：帶有 5'/3' ITR 以及由特定啟動(dòng)子驅(qū)動(dòng)的目的基因（GOI）和篩選標(biāo)記（如 Puro/Neo）。

     • Helper 質(zhì)粒（表達(dá)載體）：即本品 Super PiggyBac Transposase 表達(dá)質(zhì)粒。

   • 推薦質(zhì)量質(zhì)量比：在轉(zhuǎn)染時(shí)，Donor 質(zhì)粒與 Helper 質(zhì)粒的推薦質(zhì)量比為 2:1 至 5:1（即轉(zhuǎn)座子載體占絕對(duì)多數(shù)，避免過(guò)量轉(zhuǎn)座酶引發(fā)的“過(guò)生產(chǎn)抑制”現(xiàn)象，過(guò)多的轉(zhuǎn)座酶反而會(huì)降低整合效率）。

2. 細(xì)胞轉(zhuǎn)染與整合（Cell Transfection）：

   • 常規(guī)貼壁細(xì)胞（如 HeLa、293T、CHO）：當(dāng)細(xì)胞融合度達(dá)到 60%-70% 時(shí)，使用常規(guī)脂質(zhì)體轉(zhuǎn)染試劑（如 Lipofectamine 3000）將混合質(zhì)粒共轉(zhuǎn)染入細(xì)胞。

   • 難轉(zhuǎn)染細(xì)胞/懸浮細(xì)胞（如免疫 T 細(xì)胞、干細(xì)胞、電轉(zhuǎn)敏感株）：強(qiáng)烈建議使用核轉(zhuǎn)染（Nucleofection/電穿孔）方案。將細(xì)胞懸浮于專(zhuān)用電轉(zhuǎn)液中，加入按比例混合的質(zhì)粒后執(zhí)行特定電擊程序。

3. 抗生素加壓篩選穩(wěn)定株（Stable Line Selection）：

   • 轉(zhuǎn)染后 24-48 小時(shí)，細(xì)胞進(jìn)入正常的轉(zhuǎn)錄翻譯期。此時(shí)可取部分細(xì)胞在熒光顯微鏡下觀測(cè) Donor 載體上的熒光報(bào)告物以評(píng)估初始轉(zhuǎn)染效率。

   • 轉(zhuǎn)染 48 小時(shí)后，更換為含有相應(yīng)抗生素（如 Puromycin, G418 或 Blasticidin）的新鮮完全培養(yǎng)基。

   • 持續(xù)維持抗生素選擇壓力 7 到 14 天（每 2-3 天更換一次新鮮選擇培養(yǎng)基）。由于未整合的 Donor 質(zhì)粒會(huì)隨著細(xì)胞分裂自發(fā)稀釋丟失，只有將 ITR 片段成功整合至染色體 TTAA 位點(diǎn)上的細(xì)胞才能存活并無(wú)限傳代，從而高效建立基因表達(dá)極其穩(wěn)定的克隆。

四 核心科研應(yīng)用方向

1. 超大分子量基因片段/多基因復(fù)合物的染色體穩(wěn)定整合：傳統(tǒng)的慢病毒載體對(duì)插入片段大小有嚴(yán)格限制（通常上限為 8-9 kb，超過(guò)后病毒滴度會(huì)發(fā)生斷崖式下跌）。Super PiggyBac 系統(tǒng)對(duì)于 10 kb 至 100 kb 以上的超長(zhǎng) DNA 片段（如多亞基蛋白復(fù)合物、全長(zhǎng)基因組位點(diǎn)、多級(jí)代謝通路）仍能保持極高的整合效率，是構(gòu)建復(fù)雜基因工程菌/細(xì)胞株的首選。

2. 非病毒源性 CAR-T/CAR-NK 免疫細(xì)胞治療系構(gòu)建：在現(xiàn)代細(xì)胞免疫治療研究中，使用 Super PiggyBac 系統(tǒng)代替價(jià)格昂貴且質(zhì)控復(fù)雜的慢病毒/逆轉(zhuǎn)錄病毒進(jìn)行 CAR（嵌合抗原受體）基因的遞送。利用電穿孔將 sPBase 與 CAR-Donor 導(dǎo)入原代 T 細(xì)胞中，不僅能獲得極高的穩(wěn)定表達(dá)率，還能顯著降低病毒源引發(fā)的插入突變致癌風(fēng)險(xiǎn)，大幅度節(jié)約臨床前研發(fā)成本。

3. iPSC 誘導(dǎo)多能干細(xì)胞的無(wú)痕重編程與定向分化（Seamless iPSC Generation）：利用 sPBase 介導(dǎo)含有 Sox2, Oct4, Klf4, c-Myc 等重編程因子的轉(zhuǎn)座子整合入體細(xì)胞染色體，在誘導(dǎo)成功獲得多能干細(xì)胞（iPSC）后，再次瞬時(shí)轉(zhuǎn)入 sPBase 激活無(wú)痕切除活性，將基因組中的重編程重組框精準(zhǔn)剝離，獲得真正健康、不帶有任何外源載體殘留和遺傳疤痕的臨床級(jí)干細(xì)胞株。

4. 工業(yè)級(jí)高產(chǎn)重組蛋白/單克隆抗體工程細(xì)胞株（如 CHO 細(xì)胞）的快速快速建立：在生物制藥工業(yè)中，利用 Super PiggyBac 的多拷貝高效率整合特性，將治療性單抗的輕重鏈基因盒轉(zhuǎn)導(dǎo)入 CHO 細(xì)胞中。通過(guò)高濃度抗生素加壓，能極快篩選出染色體活躍轉(zhuǎn)錄區(qū)發(fā)生多位點(diǎn)單向串聯(lián)整合的高產(chǎn)工程克隆，大幅縮短細(xì)胞株開(kāi)發(fā)（CLD）周期。

PART 2 ENGLISH SECTION

I General Information and System Background

• Product Name: BioVector? Super PiggyBac Transposase (Available as expression plasmids or purified recombinant functional protein systems)

• System Type: Non-viral-mediated, high-efficiency mammalian genomic integration transposon framework.

• Origin and Evolutionary Engineering:

  • Natural Origin: The foundational PiggyBac (PB) transposon system was originally characterized from the cabbage looper moth (Trichoplusia ni). It represents a classic Class II DNA Transposon utilizing a coordinated "cut-and-paste" transposition mechanism.

  • Super Engineering: Super PiggyBac (sPBase) is a heavily evolved variant created via hyper-mutational screening and rational structural design of the native transposase enzyme. Compared to wild-type PB enzyme configurations, sPBase delivers manifold multi-fold increases in functional genomic integration efficiencies. It maintains strong chromosomal inserting kinetics even when managing massive cargo sizes (spanning 10 kb to over 100 kb).

• Biosafety Level: BSL-1. Operating as a completely non-viral nucleotide framework, it is incapable of generating replication-competent viral entities. It requires no specialized BSL-2 physical clearance parameters, acting as a highly secure tool in advanced genetic engineering.

II Molecular Mechanisms and Targeting Architecture

The Super PiggyBac Transposase specifically recognizes and binds to the Inverted Terminal Repeats (ITRs) flanking the payload expression cassette on a donor transposon vector. The step-by-step molecular pathway operates as follows:

1. Precise Cut-and-Paste Kinetics: The sPBase protein binds the 5' ITR and 3' ITR domains on the circular donor plasmid, folding the sequence into an active synaptic complex. It executes complete, clean double-stranded cleavage to excise the transposition cassette seamlessly away from the plasmid backbone.

2. TTAA Site Tropism: The excised cargo complex is directed into the host nucleus by the transposase machinery, which specifically searches for and integrates the passenger DNA into chromosomal regions harboring the tetranucleotide motif 5'-TTAA-3'. This insertion duplicates the TTAA target site at both integration junctions.

3. Seamless Scarless Excision: This feature represents a signature capability unique to the PiggyBac paradigm. Upon re-introducing the sPBase enzyme into an established line in the absence of a donor vector, the enzyme triggers reverse transposition. It excises the embedded cassette out of the host chromosome, restoring the original TTAA anchor site without leaving behind any genetic modifications, nucleotide deletions, or mutational scars (no scar/mutation left behind).

III Transfection Formulations, Cell Handling, and Stable Strain Enrichment

1. Co-transfection Stoichiometry (Helper-Donor Ratios):

   • The architecture deploys a traditional Helper-Donor Vector Framework:

     • Donor Vector (Transposon): Carries the 5'/3' ITR elements encapsulating the Gene of Interest (GOI) along with a mammalian selection marker (e.g., Puro, Neo, Blast).

     • Helper Vector (Transposase): The expression plasmid carrying the Super PiggyBac Transposase (sPBase) gene.

   • Recommended Mass Ratio: Investigators should balance the Donor to Helper mass ratio between 2:1 and 5:1 during transfection mix configuration. Excess helper plasmid can trigger "overproduction inhibition," where crowded transposase molecules block the ITR sites, reducing integration performance.

2. Cell Transformation and Transfection:

   • Adherent Monolayers (e.g., HeLa, 293T, CHO): At 60%-70% surface confluence, deliver the balanced plasmid formulation using standard liposomal transfection reagents (such as Lipofectamine 3000).

   • Hard-to-Transfect/Suspension Populations (e.g., primary human T-cells, hESCs, iPSCs): Nucleofection or traditional electroporation is highly recommended. Suspend target cells in designated electroporation buffers, incorporate the plasmid blend, and execute cell-specific pulse programs.

3. Antibiotic Selection and Stable Line Isolation:

   • At 24-48 hours post-transfection, the transformed populations enter log-phase expression. Evaluate starting transfection efficiencies under a fluorescence microscope to track reporter channels embedded in the donor construct.

   • At 48 hours post-delivery, change the culture broth to fresh media carrying selection antibiotics (e.g., Puromycin, G418, or Blasticidin) at pre-determined empirical working levels.

   • Maintain selection pressure for 7 to 14 days, refreshing the selective media every 2-3 days. Transient un-integrated donor circles will dilute out and degrade across cell division cycles. Only those cellular fractions that successfully anchor the ITR cassette into transcriptionally active chromosomal TTAA loci will survive and expand, quickly generating highly robust stable clonal lineages.

IV Strategic Research Applications

1. Stable Chromosomal Anchoring of Massive Payloads and Multi-Gene Cassettes: Conventional lentiviral delivery vectors suffer from strict package constraints (cargo beyond 8-9 kb triggers sharp drops in viral packaging efficiency and functional titers). The Super PiggyBac platform easily accommodates massive payloads ranging from 10 kb to over 100 kb (e.g., multi-subunit protein complexes, whole locus genomic sequences, multi-step metabolic pathways), serving as a premier non-viral vehicle for large-scale engineering.

2. Non-Viral CAR-T and CAR-NK Immunotherapy Cell Manufacturing: In cell therapy development pipelines, Super PiggyBac serves as an effective alternative to high-cost viral engineering protocols. Utilizing electroporation to introduce sPBase alongside a CAR-Donor construct into primary human lymphocytes yields high integration rates while minimizing insertional oncogenesis risks linked with viral vectors.

3. Scarless Reprogramming and Differentiation of Induced Pluripotent Stem Cells (iPSCs): Enables sPBase-mediated delivery of pluripotency factors (Sox2, Oct4, Klf4, c-Myc) into somatic cell lines. Once pluripotency is established, a second transient delivery of sPBase excises the integration cassette cleanly away, leaving behind clean, clinical-grade iPSC lines free of vector fragments or structural modifications.

4. Accelerated Cell Line Development (CLD) for Industrial Biologics Production (e.g., CHO Factories): In bioprocess manufacturing pipelines, Super PiggyBac leverages its multi-copy integration capability to transfer monoclonal antibody heavy- and light-chain cassettes into production-grade CHO cells. High-stringency antibiotic screening rapidly enriches for highly productive, stable clones that have anchored the transgene into hyper-active transcription hubs.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號(hào):1843439339

網(wǎng)址

http://www.nedfriskphoto.com